Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Sarcoma 8Melanoma 3Hemangiosarcoma 3Breast Neoplasms 3Prostatic Neoplasms 2Osteosarcoma 2Neoplasms 2Leiomyosarcoma 2Carcinosarcoma 2Carcinoma, Endometrioid 2Vascular Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Tertiary Lymphoid Structures 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Liposarcoma 1Kidney Neoplasms 1Histiocytoma, Malignant Fibrous 1Hemangioendothelioma, Epithelioid 1

Interventions

durvalumab 1Vinblastine 1Methotrexate 1Gemcitabine 1Doxorubicin 1Cystectomy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bladder Adenocarcinoma × durvalumab × Sarcoma × Clear all
NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

Phase 2 Terminated
7 enrolled 9 charts
GenitourinarySarcoma

Bladder Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡